560.00
-8.2(-1.44%)
Currency In USD
Previous Close | 568.2 |
Open | 567.34 |
Day High | 570 |
Day Low | 559.31 |
52-Week High | 1,165.85 |
52-Week Low | 476.49 |
Volume | 602,753 |
Average Volume | 989,582 |
Market Cap | 58.34B |
PE | 14.11 |
EPS | 39.7 |
Moving Average 50 Days | 563.95 |
Moving Average 200 Days | 621.93 |
Change | -8.2 |
If you invested $1000 in Regeneron Pharmaceuticals, Inc. (REGN) 10 years ago, it would be worth $1,034.26 as of September 15, 2025 at a share price of $560. Whereas If you bought $1000 worth of Regeneron Pharmaceuticals, Inc. (REGN) shares 5 years ago, it would be worth $965.68 as of September 15, 2025 at a share price of $560.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
GlobeNewswire Inc.
Sep 08, 2025 10:30 AM GMT
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will support further Phase 3 development TARRYTOWN, N.Y., Sept
Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
GlobeNewswire Inc.
Sep 04, 2025 8:05 PM GMT
TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Monday, September 8, 2025.
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
GlobeNewswire Inc.
Aug 20, 2025 3:19 PM GMT
TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD®